Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy.
Fiore G, Weckwarth W, Paetzold K, Albertí Servera L, Gies M, Rosenhauer J, Antoniolli M, Nassiri S, Schmeing S, Dettling S, Soni B, Majety M, Krug AB, Hoves S, Wolf MJ. Fiore G, et al. Among authors: hoves s. Front Immunol. 2024 Nov 7;15:1433119. doi: 10.3389/fimmu.2024.1433119. eCollection 2024. Front Immunol. 2024. PMID: 39575246 Free PMC article.
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Schlenker R, Schwalie PC, Dettling S, Huesser T, Irmisch A, Mariani M, Martínez Gómez JM, Ribeiro A, Limani F, Herter S, Yángüez E, Hoves S, Somandin J, Siebourg-Polster J, Kam-Thong T, de Matos IG, Umana P, Dummer R, Levesque MP, Bacac M. Schlenker R, et al. Among authors: hoves s. Med. 2024 Jul 12;5(7):759-779.e7. doi: 10.1016/j.medj.2024.03.015. Epub 2024 Apr 8. Med. 2024. PMID: 38593812 Free article.
Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages.
Murgaski A, Kiss M, Van Damme H, Kancheva D, Vanmeerbeek I, Keirsse J, Hadadi E, Brughmans J, Arnouk SM, Hamouda AEI, Debraekeleer A, Bosteels V, Elkrim Y, Boon L, Hoves S, Vandamme N, Deschoemaeker S, Janssens S, Garg AD, Vande Velde G, Schmittnaegel M, Ries CH, Laoui D. Murgaski A, et al. Among authors: hoves s. Cancer Res. 2022 Oct 17;82(20):3785-3801. doi: 10.1158/0008-5472.CAN-22-0094. Cancer Res. 2022. PMID: 35979635 Free PMC article.
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Bissinger S, Hage C, Wagner V, Maser IP, Brand V, Schmittnaegel M, Jegg AM, Cannarile M, Watson C, Klaman I, Rieder N, González Loyola A, Petrova TV, Cassier PA, Gomez-Roca C, Sibaud V, De Palma M, Hoves S, Ries CH. Bissinger S, et al. Among authors: hoves s. Sci Transl Med. 2021 Jun 16;13(598):eabd4550. doi: 10.1126/scitranslmed.abd4550. Sci Transl Med. 2021. PMID: 34135110
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg AM, Cannarile MA, Watson C, Babitzki G, Korski K, Klaman I, Teixeira P, Hoves S, Ries C, Meneses-Lorente G, Michielin F, Christen R, Rüttinger D, Weisser M, Delord JP, Cassier P. Machiels JP, et al. Among authors: hoves s. J Immunother Cancer. 2020 Oct;8(2):e001153. doi: 10.1136/jitc-2020-001153. J Immunother Cancer. 2020. PMID: 33097612 Free PMC article. Clinical Trial.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse E, De Palma M, Zippelius A. Kashyap AS, et al. Among authors: hoves s. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551. doi: 10.1073/pnas.1902145116. Epub 2019 Dec 30. Proc Natl Acad Sci U S A. 2020. PMID: 31889004 Free PMC article.
38 results